Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bot Image

Virtualizing Healthcare with Human-Centric Technology

Dr. Patrick Carroll, Chief Medical Officer at Vida Health, discusses the importance of using a “whole health” approach to chronic disease management, how and why the human connection with a...

Impetus Digital

- PMLiVE

EIT Health launches the WorkInHealth Foundation

The new initiative aims to find new talent to meet increasing digital demands

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Impetus Digital

- PMLiVE

FDA delays Merck’s pneumococcal vaccine Vaxneuvance

It is predicted that the vaccine could make over $1bn in peak sales

- PMLiVE

ICR scientists create AI test to predict cancer drug combinations

The technique uses artificial intelligence (AI) to analyse large-scale protein data from tumour samples

- PMLiVE

FDA grants Pfizer/BioNTech expanded EUA for an additional COVID-19 vaccine booster

The second booster authorisation is for those aged 50 years and older to promote high levels of protection against COVID-19 in the most vulnerable groups

- PMLiVE

FDA approves Novartis’ Pluvicto for prostate cancer

The treatment is the first FDA approved targeted radioligand therapy for mCRPC patients

- PMLiVE

Pfizer receives Breakthrough Therapy Designation from FDA for RSV vaccine candidate

There are currently no preventative, therapeutic or vaccine options for older adults diagnosed with RSV

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

Merck’s Keytruda receives FDA approval for advanced endometrial cancer

The approval was based on new data from the KEYNOTE-158 trial

- PMLiVE

FDA to review requirements for future booster shots for COVID-19

The meeting will be streamed live on the FDA’s YouTube channel and a webcast will be provided on the FDA website

- PMLiVE

Moderna applies to FDA for authorisation for second COVID-19 booster shot for all adults

The second booster shot would be for adults 18 years and over who have already had one authorised COVID-19 booster shot

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links